What is Enterin?
Enterin operates at the intersection of biotechnology and neurology, focusing exclusively on the complex challenges presented by neurodegenerative conditions. The company is dedicated to advancing the scientific understanding of Parkinson's disease, aiming to translate intricate biological insights into meaningful patient care solutions. By targeting both the patient population and the medical professionals who manage these chronic conditions, Enterin has established itself as a critical player in the development of innovative treatment modalities. Their operational model emphasizes rigorous research and development, ensuring that every strategic milestone is backed by empirical data and a commitment to improving long-term health outcomes in the neurology sector.
How much funding has Enterin raised?
Enterin has raised a total of $13.1M across 3 funding rounds:
Series A
$12.7M
Debt
$150K
Debt
$293K
Series A (2017): $12.7M with participation from New Ventures III
Debt (2020): $150K led by PPP
Debt (2021): $293K supported by PPP
Key Investors in Enterin
New Ventures III
New Ventures III is a healthcare venture platform that invests throughout the healthcare industry, ranging from early-stage startups to developed drug programs.
PPP
Public-Private Partnership
What's next for Enterin?
With the recent influx of capital, Enterin is well-positioned to scale its research initiatives and accelerate the development of its therapeutic pipeline. The company's focus will likely shift toward expanding its clinical trial capabilities and refining its diagnostic insights to better serve the global Parkinson's community. As the firm transitions into this next phase of growth, the emphasis will remain on maintaining high-authority research standards while navigating the regulatory landscape of the pharmaceutical industry. Investors and stakeholders will be monitoring the company's ability to convert its current financial momentum into tangible, market-ready medical advancements that address the unmet needs of those suffering from neurodegenerative diseases.
See full Enterin company page
